Combination therapies, for

Hodgkin s disease, lymphocytic lymphoma, histiocytic lymphoma, mycosis fungoides, testicular cancer, Kaposi s sarcoma, breast cancer Acute leukemia, combination therapy for various cancers... 

Chan HL, Leung NW, Hui AY, Wong VW, Liew CT, Chim AM, Chan FK, Hung LC, Lee YT, Tam JS, Lam CW, Sung JJ (2005b) A randomized, controlled trial of combination therapy for... 

Wolters LM, van Nunen AB, Honkoop P, Vossen AC, Niesters HG, Zondervan PE, de Man RA (2000) Lamivudine-high dose interferon combination therapy for chronic hepatitis B patients co-infected with the hepatitis D virus. J Viral Hepat 7 428 34 Wong DK, Cheung AM, O Rourke K, Naylor CD, Detsky AS, Heathcote J (1993) Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A metaanalysis. Ann Intern Med 119 312-323... 

Table 3 Standard combination therapy for chronic hepatitis C...

Antiretroviral Combination Therapy for Drug-Naive and for Treatment-Experienced Patients... 

Yuen MF, Lai CL (2007) Combination therapy for chronic hepatitis B simultaneous or sequential Am J Gastroenterol 102(1) 105-106... 

Very limited information is available on the use of combination therapy for potentiation of HbF production. Erythropoietin has shown inconsistent results in small numbers of patients. When used with hydroxyurea, erythropoietin has been shown to increase HbF to a greater extent than hydroxyurea alone, and although more studies are needed, this may provide an option for patients who do not respond to hydroxyurea alone.27... 

Ogasrtro (Lansoprazole) Duodenal ulcer Gastro-oesophageal reflux Helicobacter infections 2.3 0.8 1994 - UK 1995 - US Once daily, except when used as part of combination therapy for H. pylori and for hypersectetory conditions. Twice-daily when dose >120 mg. 

A 45-year-old male on combination therapy for remission-maintenance acute lymphocytic leukemia develops suprapubic pain, dysuria, and hematuria. Evidence of hemorrhage and inflammation is apparent on cystoscopy of the urinary bladder. Which of the following agents most likely caused these findings ... 

The principal use of niacin is for mixed hyperlipidemia or as a second-line agent in combination therapy for hypercholesterolemia. It is a first-line agent or alternative for the treatment of hypertriglyceridemia and diabetic dyslipidemia. 

A variety of pharmacologic approaches are available and may be prescribed as single or combination therapy for prophylaxis of PONV. See Table 27-8 for doses of specific agents. 

Compston JE, Watts NB (2002) Combination therapy for postmenopausal ostoporosis. Clin Endocrinol 56 565-569... 

Fig. 10.19 ApoUpoprotein E APOE)-m dteA cognitive performance in patients with Alzheimer s disease treated with a combination therapy for 1 yr...

Nifedipine is used for preventing and relieving angina pectoris attacks, for hypertension, and as an ingredient in combination therapy for chronic cardiac insufficiency. Synonyms of this drug are adalat, corinfar, procardia, and nifecor. 

Monotherapy - Initiate monotherapy in patients not adequately controlled with diet and exercise at 15 or 30 mg once daily. For patients who respond inadequately to the initial dose of pioglitazone, the dose can be increased in increments up to 45 mg once daily. Consider combination therapy for patients not responding adequately to monotherapy. 

Combination therapy - For maximal therapeutic effect in combination with an HMG-CoA reductase inhibitor, the recommended dose of colesevelam is 3 tablets taken twice daily with meals or 6 tablets taken once daily with a meal. Doses of 4 to 6 tablets/day have been shown to be safe and effective when coadministered with an HMG-CoA reductase inhibitor or when the 2 drugs are dosed apart. 

Capsules/Tablets/Oral solution-The safety and efficacy of ribavirin and interferon alfa-2b or peginterferon alfa-2a combination therapy for the treatment of HCV have not been established in patients coinfected with HIV or HBV. 

Combination therapy - For toxicities likely to be associated with zalcitabine (eg, peripheral neuropathy, severe oral ulcers, pancreatitis, elevated liver function tests, especially in patients with chronic hepatitis B see Warnings and Precautions), interrupt or reduce dose. For severe toxicities or those persisting after dose reduction, interrupt zalcitabine therapy. For recipients of combination therapy with zalcitabine and other antiretrovirals, base dose adjustments or interruption for either drug on the known toxicity profile of the individual drugs. 

Nigro ND, Vaitkevicius VK, Considine B Jr. Combined therapy for cancer of the anal canal a preliminary report. Dis Colon Rectum 1974 17(3) 354—356. 

Hydroxychloroquine Plaquenil) and chloroquine Ara-len) are 4-aminoquinoline antimalarial drugs that possess modest DMARD activity. They are indicated for the treatment of rheumatoid arthritis and systemic lupus erythematosus their use as antimalarials is detailed in Chapter 53. The onset of action of these drugs is longer than that of other DMARDs, and their side effects are relatively mild. Because of this, these agents show promise as ingredients of combination therapies for rheumatoid arthritis. 

A 32-year-old Haitian man has acute-onset confusion and suicidal ideation. Two weeks ago he began combination therapy for multi-drug resistant pulmonary tuberculosis. He has a history of depression that required intermittent treatment in the past. Which of the following antitubercular agents is responsible for the patient s neurological symptoms ... 

Tenofovir disoproxil fumarate (Viread) is a prodrug of tenofovir, a phosphorylated adenosine nucleoside analogue, and is the only available agent of its class. It is converted by cellular enzymes to tenofovir diphosphate, which competes with deoxyadenosine triphosphate (dATP) for access to reverse transcriptase and causes chain termination following its incorporation. Tenofovir was approved as part of a combination therapy for HIV in adults who failed treatment with other regimens it appears to be effective against HIV strains that are resistant to NRTIs. The pharmacokinetic properties of tenofovir are provided in Table 51.2. 

---